In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
NeoMatrix: A “Pap Smear for Breast Cancer”
Neomatrix of Irvine, Calif., has developed a fully automated, non-invasive device to assess a patient’s risk of developing breast cancer.
Quantum Immunologics’ Alternative to Chemotherapy
The company’s vaccine technology is based on the universal tumor antigen, which has been expressed in all human cancers studied so far.
An Amplifier for Diagnostic Tests
Sword Diagnostics of Illinois has developed a “next-generation” system to increase the sensitivity (and therefore accuracy) of diagnostic tests.
LAMP May Light the Way to New Generation of Vaccines
LAMP (Lysosome-Associated Membrane Protein) is a gene that has been shown to enhance immune response when incorporated into a DNA vaccine.
Defining a Radiation Target with Augmenix
The company’s SpaceOAR System is designed to temporarily separate organs during radiotherapy so that normal tissues are spared, and to mark tumor resection sites to allow for targeted therapy.
Access Pharma (ACCP.OB) Product Development Update – Sponsored Post
Access Pharmaceuticals (OTC: ACCP.OB, “Access”) develops and commercializes products for the treatment and supportive care of cancer patients.
Dimera Fights the “Silent Killer”
According to the American Heart Association, heart disease is the number one killer of women over age 25–more than the next five causes of death, or all forms of cancer, combined.
